帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好,仅出现轻度胃肠道不良事件,并展现出有前景的活性,值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:TIM-3/Galectin-9 and CD160 expression in salivary adenoid cystic carcinoma.
TIM-3/Galectin-9 and CD160 expression in salivary adenoid cystic carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
TIL 低密度是 SACC 微环境的特征,同时伴有 TIM-3、Gal-9 和 CD160 的上调。然而,SACC 中 TIM-3、Gal-9 和 CD160 在基质中的表达依赖于 TIL 数量,这代表了潜在的治疗靶点。
研究T细胞免疫球蛋白和黏蛋白结构域包含-3(TIM-3)、半乳糖凝集素9(Gal-9)、CD160表达及TIL(肿瘤浸润淋巴细胞)(TILs)与唾液腺腺样囊性癌(SACC)临床病理特征的相关性。
对60例SACC进行免疫组化染色,以评估TIM-3、Gal-9和CD160的表达,并通过秩和检验分析TIM-3、Gal-9、CD160表达与临床病理特征之间的相关性。通过卡方检验分析SACC间质中TILs与TIM-3、Gal-9和CD160表达的关联。
TIM-3和CD160过表达与SACC复发相关(分别为p = 0.029,p = 0.007)。Gal-9高表达与病理分级相关(p = 0.018)。SACC中TILs的平均百分比为18.2%,且大多数TILs更可能发生于小唾液腺(p = 0.038)。在肿瘤细胞以及TILs中,分别观察到TIM-3、Gal-9和CD160表达之间存在两两正相关。
Investigating T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), Galectin 9 (Gal-9), CD160 expression and tumor-infiltrating lymphocytes (TILs) and correlation with clinicopathological characteristics of salivary adenoid cystic carcinoma (SACC).
Sixty cases of SACC were detected by immunohistochemical staining to evaluate TIM-3, Gal-9, and CD160 expression and analyze the correlation between TIM-3, Gal-9, CD160 expression and clinicopathologic features by rank-sum test. The association of TILs with TIM-3, Gal-9, and CD160 expression in SACC stromal was done by Chi-square test.
TIM-3 and CD160 overexpression were correlated with recurrence of SACC (p = 0.029, p = 0.007, respectively). High Gal-9 expression was correlated with pathological classification (p = 0.018). The average percentage of TILs was 18.2% in SACC and most of TILs were more likely to occur in minor salivary glands (p = 0.038). Pairwise positive correlations were observed between the expression of TIM-3, Gal-9, and CD160 in tumor cells as well as in TILs, respectively.
Low density of TILs was characteristic of the SACC microenvironment, with upregulation of TIM-3, Gal-9, and CD160 all occurring. However, TIM-3, Gal-9, and CD160 expression in the stromal dependent on the number of TILs represent potential therapeutic targets in SACC.
MEMBER ACCOUNT
登录成功会直接打开下一页。